Method for screening and verifying quality marker of gastrodia elata for improving cerebral ischemia reperfusion injury
Through UHPLC-Q-TOF/MS technology and gray correlation analysis, anti-inflammatory and antioxidant quality markers in Gastrodia elassum decoction were screened and its therapeutic effect was verified in the zebrafish model, which solved the treatment of Gastrodia elassum in the treatment of cerebral ischemia and reperfusion injury The problem of unknown mechanism has realized the systematic analysis of the ingredients of the Tamsui Decoction and the screening of the medicinal substances, providing a scientific basis for the clinical application of traditional Chinese medicine.
Patent Information
- Application Number
- CN202410962106.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-01
AI Technical Summary
The prior art lacks systematic reports on the internal and external components of Gastrodia elata decoction liquid and the mechanism of improving cerebral ischemia and reperfusion injury, and it is difficult to effectively screen out the medicinal substances for Gastrodia elata for treating cerebral ischemia and reperfusion injury.
UHPLC-Q-TOF/MS technology was used to analyze the internal and external components of the Gastrodia elassum decoction. Combined with the gray correlation analysis method, anti-inflammatory and antioxidant quality markers were screened, and mechanism verification was carried out on the zebrafish stroke model to verify the screened The therapeutic effect of the monomer component on cerebral ischemia and reperfusion injury.
UHPLC-Q-TOF-MS detection and spectrometry correlation analysis were used to screen gastrointestinal, para-hydroxybenzaldehyde as the main anti-inflammatory and antioxidant mass markers, verifying that it significantly reduces thrombosis in zebrafish models and cerebral infarction area provide scientific basis for Gastrodia elata for the treatment of cerebral ischemia and reperfusion injury.
Smart Images

Figure CN118883752A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for screening a quality marker of angiogenesis promoted by Cuscuta australis, and specifically belongs to the field of extraction of active ingredients of traditional Chinese medicine and quality evaluation of traditional Chinese medicine. Background Art
[0002] Gastrodia elata is derived from the dried tuber of Gastrodia elata Bl., a plant of the genus Gastrodia in the orchid family. It was first recorded in Shennong's Herbal Classic. It is also known as Chijian, Mingtianma, Dingfengcao, etc., and is listed as a top-grade product. The pharmacopoeia records that Gastrodia elata has the efficacy of calming wind and stopping spasms, calming liver yang, and removing wind and unblocking collaterals. In the clinical practice of traditional Chinese medicine, Chinese herbal medicine pieces have formed an oral administration method mainly based on decoctions. Whether the preparation of the decoction of medicinal materials will lead to changes in chemical composition, and whether the decoction of Gastrodia elata also needs to detect the above compounds to determine the quality of the decoction are unknown. In addition, Chinese medicine prescriptions have the characteristics of multi-component, multi-target, multi-pathway, and integrated regulation. Based on existing literature reports, Gastrodia elata can eliminate inflammation, resist oxidative damage, inhibit cell apoptosis, and upregulate neuroprotective genes, thereby showing protective effects on ischemic brain injury such as reducing cerebral infarction area and improving neurobehavioral scores. Therefore, it is of great clinical significance to actively seek effective active ingredients of Gastrodia elata in the treatment of cerebral ischemia-reperfusion injury.
[0003] Based on this, the present invention also dynamically administers the decoction of Gastrodia elata to rats with cerebral ischemia-reperfusion injury to monitor the changes of redox indexes and inflammatory indexes in rat serum, and uses the zebrafish stroke model to verify the mechanism of the screened monomer components. At present, there are few reports on the material basis of the efficacy of Gastrodia elata in treating cerebral ischemia-reperfusion injury, and there is a lack of systematic reports on the in vivo and in vitro components of Gastrodia elata and the mechanism of improving cerebral ischemia-reperfusion injury. Therefore, based on the in vivo and in vitro chemical component analysis of Gastrodia elata decoction and the verification of the relevant mechanism, the quality markers of Gastrodia elata in improving cerebral ischemia-reperfusion injury are screened, which has important practical significance for the clinical use of Gastrodia elata. Summary of the invention
[0004] The purpose of the present invention is to carry out the identification of the in vivo and in vitro components of a single Chinese medicine based on UHPLC-Q-TOF / MS technology, to clarify the components of Gastrodia elata decoction migrating into the blood of rats, to correlate the screened chemical components with the efficacy indicators, and to select 3 monomer components to verify the relevant mechanism of the zebrafish stroke model, so as to provide a scientific basis for screening the efficacy material basis of Gastrodia elata in improving cerebral ischemia-reperfusion injury.
[0005] The technical solution of the present invention is as follows:
[0006] A method for screening gastrodia elata anti-inflammatory and antioxidant quality markers, comprising the following steps:
[0007] S1: Gastrodia elata was decocted according to the standard decoction method, and the two filtrates were combined and concentrated into a 0.81 g / mL decoction. The decoction was administered to rats with cerebral ischemia-reperfusion injury at dynamic time points, and the serum of rats at different time points was collected for the detection of oxidative stress indicators and inflammatory factor indicators;
[0008] S2: UHPLC-Q-TOF / MS technology was used to qualitatively analyze the in vivo and in vitro components of Gastrodia elata decoction, analyze the migrating components in rat blood and draw a line graph of the response intensity of each component;
[0009] S3: Correlate the dynamic changes of each efficacy index in S1 with the changes in the response intensity of each component in S2, construct the anti-inflammatory and antioxidant spectrum-effect relationship of Gastrodia elata, and preliminarily screen out the components with strong correlation;
[0010] S4: The monomer components selected in S3 were screened for their maximum safe concentration in zebrafish, and finally a multi-dimensional anti-inflammatory and antioxidant activity test was conducted on the zebrafish stroke model, including the detection of anti-thrombotic rate, cell apoptosis count, oxidative stress indexes and inflammatory factor indexes, to verify the above spectrum-effect related results.
[0011] Furthermore, in step S3, the spectrum-effect correlation method is grey correlation analysis; and components with a correlation degree greater than 0.6 are used as anti-inflammatory and antioxidant quality markers.
[0012] Further, in step S2, the chromatographic conditions of ultra-performance liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry are as follows: using a Waters UPLC BEH C18 chromatographic column, column temperature: 30°C, flow rate: 0.4mL / min, injection volume of 5μL, mobile phase A is 0.1% formic acid in water, and mobile phase B is acetonitrile containing 0.1% formic acid: 0-3.5min, 5%-15% B; 3.5-6min, 15%-30% B; 6-6.5min, 30% B; 6.5-12min, 30%-70% B; 12-12.5min, 70% B; 12.5-18min, 70%-100% B; 18-25min, 100% B; 25-26min, 100%-5% B; 26-30min, 5% B. Mass spectrometry conditions are as follows: AB 5600Triple TOF mass spectrometer can perform primary and secondary mass spectrometry data acquisition based on the IDA function under the control of the control software (Analyst TF 1.7, AB Sciex). In each data acquisition cycle, the molecular ions with the strongest intensity greater than 100 are screened to collect the corresponding secondary mass spectrometry data. Bombardment energy: 40eV, collision energy difference: 20V, 15 secondary spectra every 50ms. The ESI ion source parameters are set as follows: nebulizer pressure (GS1): 55Psi, auxiliary gas pressure: 55Psi, air curtain pressure: 35Psi, temperature: 550℃, spray voltage: 5500V (positive ion mode) or -4000V (negative ion mode).
[0013] The present invention also discloses a screening method as described above, wherein the anti-inflammatory and antioxidant quality markers of Gastrodia elata are screened out as gastrodin, p-hydroxybenzyl alcohol and p-hydroxybenzaldehyde.
[0014] The present invention also discloses a mechanism verification of a gastrodia elata anti-inflammatory and antioxidant quality marker on a zebrafish stroke model. First, after dynamic administration to rats with cerebral ischemia-reperfusion injury according to the above method, the neurological deficits, cerebral infarction area and redox and inflammatory factor indicators in the rats' serum are detected; then, the gastrodia elata anti-inflammatory and antioxidant extract is semi-quantitatively analyzed by ultra-performance liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry, and the response intensity changes of the screened chemical components are correlated with the dynamic changes of the efficacy indicators by spectrum-effect correlation; then, the maximum safe concentration of the screened monomer components is screened on zebrafish, and finally, multi-dimensional anti-inflammatory and antioxidant activity detection is carried out on the zebrafish stroke model, including the detection of anti-thrombotic rate, cell apoptosis count, oxidative stress indicators and inflammatory factor indicators, to verify the above spectrum-effect correlation results.
[0015] The beneficial effects of the present invention are:
[0016] (1) The in vivo and in vitro components of Gastrodia elata decoction were comprehensively and systematically analyzed using UHPLC-QTOF-MS detection technology and spectral-effect correlation analysis grey correlation analysis. Ten anti-inflammatory and antioxidant quality markers were screened out from 91 blood-entering prototypes and metabolic chemical components of Gastrodia elata.
[0017] (2) The present invention has found through spectrum-effect correlation studies that gastrodin, p-hydroxybenzyl alcohol and p-hydroxybenzaldehyde as its main components have strong pharmacodynamic effects. After p-hydroxybenzyl alcohol enters the body and undergoes metabolism, the metabolite p-hydroxybenzaldehyde produced also shows a high correlation.
[0018] (3) The mechanism of anti-inflammatory and antioxidant quality markers of Gastrodia elata was verified in the zebrafish stroke model. The anti-thrombotic effect rate of the screened quality markers, gastrodin, was 46.8%, p-hydroxybenzyl alcohol was 88.6%, and p-hydroxybenzaldehyde was 84.8%. Both thrombosis formation and quantitative area were significantly reduced. This method provides a unique idea for verifying the quality markers screened by the spectrum-effect correlation analysis method, and also provides further reference and inspiration for the clinical application of traditional Chinese medicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 A is the effect of dynamic administration of Gastrodia elata decoction on the neurological deficit score of rats with cerebral ischemia-reperfusion injury; Figure 1 B is the effect of dynamic administration of Gastrodia elata decoction on the cerebral infarction area ratio of rats with cerebral ischemia-reperfusion injury; Figure 1 C shows the effect of dynamic administration of Gastrodia elata decoction on TTC staining of brain tissue in rats with cerebral ischemia-reperfusion injury.
[0020] Figure 2 To study the effect of Gastrodia elata on the levels of SOD, MDA, TNF-α, IL-6 and IL-1β in serum of rats with cerebral ischemia-reperfusion injury.
[0021] Figure 3 This is a time line graph of MDA, TNF-α, IL-6, IL-1β, and SOD in rat serum.
[0022] Figure 4 It is a metabolite in rat drug-containing serum.
[0023] Figure 5 The metabolic pathways of barleyson glycosides and gastrodin in rats.
[0024] Figure 6 A is the transitional component Gastrodin, P-hydroxybenzyl alcohol, 4-hydroxybenzaldehyde, Parishin, Parishin B, Parishin C, Parishin E, Succinic acid response intensity time line graph in rats; Figure 6 B is a time line graph of the response intensity of the transitional components Palmitic acid and Citric acid in rats.
[0025] Figure 7 This is a summary of the phenotypes of zebrafish treated with various concentrations of gastrodin.
[0026] Figure 8 A summary of the phenotypes of zebrafish treated with various concentrations of p-hydroxybenzyl alcohol.
[0027] Fig. 9 The figure is a summary of the phenotypes of zebrafish treated with different concentrations of p-hydroxybenzaldehyde.
[0028] Fig.10 This is a summary of cerebral thrombosis in each group of zebrafish.
[0029] Fig.11 It is a bar graph of the thrombus area in the zebrafish brain of each group.
[0030] Fig.12 This is the overall idea diagram for screening and validating the quality markers of Gastrodia elata in improving cerebral ischemia-reperfusion injury. DETAILED DESCRIPTION
[0031] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further described below in conjunction with specific embodiments and diagrams.
[0032] Example 1
[0033] 1. Setting of dynamic drug administration time
[0034] Before the experimental study, this paper conducted a literature review on the improvement of Gastrodia elata and traditional Chinese medicine on cerebral ischemia-reperfusion injury. After consulting 31 relevant literatures, it was found that traditional Chinese medicine had therapeutic or protective effects at 3, 5, 6, 7, 8, 9, 14, 15, 21, and 28 days after administration. The literature on Gastrodia elata administration showed that the ischemic conditions of brain neuronal cells and brain TTC in model rats were significantly improved after 7d and 14d of administration. Therefore, this experiment chose to set up dynamic administration at five time points: 1d, 3d, 7d, 10d, and 14d to observe the therapeutic effect of Gastrodia elata on cerebral ischemia-reperfusion injury.
[0035] 2. Establishment, grouping and drug administration of cerebral ischemia-reperfusion injury model
[0036] All rats were fasted for 12 hours before surgery. The MCAO model was prepared by Zea Longa's modified suture method: the model rats were anesthetized by intraperitoneal injection of 20% urethane (10 mL / kg). After anesthesia, the rats were fixed in supine position, an incision was made in the middle of the neck, the right internal and external carotid arteries and the common artery were exposed, and permanent ligation was made at the proximal end of the external carotid artery and the common carotid artery, and the internal carotid artery was clamped with an artery clamp. A small incision was made with scissors about 1 cm from the distal end of the common carotid artery to the bifurcation of the internal and external carotid arteries, and a pre-prepared fishing line (with wax embedded tip, diameter of 0.26 mm, marked at 18-22 mm) was inserted into the internal carotid artery through the common carotid artery and into the skull. The fishing line was inserted until resistance was stopped, that is, about 18-20 mm was inserted from the bifurcation, and the fishing line was ligated together with the common carotid artery, and the skin was sutured. The wound was covered with gauze moistened with saline, and the rat was placed in a prone position. After 2 hours of ischemia, the fishing line was removed from the blood vessels and blood was perfused for 24 hours. During this period, the rats were kept warm and hydrated.
[0037] The 42 rats with successful modeling were divided into 7 groups according to the random number table method, namely, sham operation group, model (0-day drug administration) group, 1-day drug administration group, 3-day drug administration group, 7-day drug administration group, 10-day drug administration group, and 14-day drug administration group, with 6 rats in each group. After successful modeling, the sham operation group and the model group were gavaged with normal saline, and the five dynamic detection groups were gavaged with a medium dose of Gastrodia elata decoction (0.81g / mL) for 1, 3, 7, 10, and 14 days, respectively. All groups were gavaged once a day (10mL / kg).
[0038] 3. Pharmacodynamic evaluation
[0039] 3.1. Neurological function scores of rats
[0040] Two hours after the last administration, the neurobehavior of the rats was evaluated according to the Zea-Longa 5-point neurological deficit scoring standard. Scoring criteria: no signs of neurological deficit were 0 points; slight forelimb flexion was 1 point; severe forelimb flexion and decreased resistance to lateral pushing were 2 points; spontaneous rotation or contralateral rotation to the affected side was 3 points; decreased consciousness and inability or difficulty to move was 4 points; no response to stimulation was 5 points.
[0041] 3.2 TTC staining
[0042] Three rats were selected from each group and anesthetized by intraperitoneal injection of 20% urethane (5 mL / kg), and then decapitated. The brain tissue was removed and placed in a -20°C refrigerator for 30 minutes. When the brain was semi-hard, coronal sections were cut from the frontal pole to the occipital pole, a total of 5 slices with a thickness of about 2 μm. The brain slices were placed in a 2% (w / v) TTC solution prepared in phosphate buffered saline (PBS) for staining, first incubated in a 37°C incubator in the dark for 15 minutes, and then the brain slices were turned over and incubated for another 15 minutes, for a total of 30 minutes, to ensure that the brain slices were evenly stained. Finally, the brain slices were removed and the excess liquid was absorbed with filter paper, observed and photographed. Normal brain tissue was dark red after staining, and ischemic brain tissue was white. ImageJ analysis software was used to analyze and calculate the volume percentage of cerebral infarction foci, cerebral infarction volume percentage (%) = total area of infarcted brain tissue / total area of brain tissue x 100%.
[0043] 3.3. Detection of serum index levels
[0044] The dynamic monitoring group was tested for interleukin IL-6, IL-1β, and tumor necrosis factor (TNF-α) levels according to the instructions of the EILSA kit. The malondialdehyde (MDA) content was detected by microplate method. The superoxide dismutase (SOD) content was detected by spectrophotometry.
[0045] 4. Data processing
[0046] 4.1 Effects of Gastrodia elata on neurological deficit scores and cerebral infarction area in rats
[0047] After successful modeling, the rats in the sham operation group had no obvious neurological deficits, while the neurological deficit scores of the rats in the model group showed a significant upward trend (P<0.01), indicating that cerebral ischemia-reperfusion would cause certain damage to the neurological function of rats. The modeling of this experiment was successful. Compared with the model group, the neurological deficit scores of the rats in the 7d, 10d, and 14d groups gavaged with Gastrodia elata decoction were reduced (P<0.01). Figure 1 A.
[0048] The results of TTC staining showed that there were no white infarction lesions in the sham operation group. The other groups all had obvious pale areas, that is, there was a certain amount of infarction. Compared with the sham operation group, the percentage of cerebral infarction area in the model group rats increased significantly (P<0.01), proving that the model was successful. Compared with the model group, the 3d, 7d, 10d, and 14d groups of Gastrodia elata oral administration significantly reduced the cerebral infarction area (P<0.01), indicating that Gastrodia elata has a certain repair effect on ischemic brain tissue damage. Figure 1 B, C.
[0049] 4.2 Effects of Gastrodia elata on the levels of various indicators in rat serum
[0050] 4.2.1. Changes in serum oxidative stress indicators MDA and SOD levels in rats of each group
[0051] Compared with the sham operation group, the serum MDA level of the rats in the model group was significantly increased (P ≤ 0.01), and the SOD level was significantly decreased (P < 0.01). Compared with the model group, the serum MDA level of the rats gavaged with Gastrodia elata decoction for 7d, 10d, and 14d was significantly decreased (P ≤ 0.01), and the SOD level was significantly increased (P ≤ 0.01). Figure 2 .
[0052] 4.2.2 Changes in serum levels of inflammatory factors TNF-α, IL-6, and IL-1β in rats of each group
[0053] Compared with the sham operation group, the levels of TNF-α, IL-6, and IL-1β in the serum of the rats in the model group were significantly increased (P≤0.01). Compared with the model group, the levels of TNF-α, IL-6, and IL-1β in the serum of the rats gavaged with Gastrodia elata decoction at 7d, 10d, and 14d were significantly decreased (P≤0.01). Figure 2 .
[0054] In general, intragastric administration of Gastrodia elata decoction for 7, 10, and 14 days has a good improvement effect on cerebral ischemia-reperfusion injury.
[0055] 4.3. Drug efficacy-time line graph at different time points
[0056] After the CIRI model was established, the rats showed spontaneous rotation or rotation from the contralateral side to the affected side. At the same time, the content of relevant efficacy indicators in the drug-containing serum of the rats was detected, and it was found that there was a significant difference between the model group and the sham operation group, indicating that the model was successfully established. After administration, the content of oxidative stress indicators and inflammatory indicators in the serum of rats in each group was detected. It was found that the content of SOD, MDA, IL-1β, IL-6, and TNF-a in the drug-containing serum of rats in the dynamic monitoring group was significantly different from that in the model group. Therefore, the above five efficacy indicators can be used for subsequent spectrum-effect correlation analysis. The efficacy-time line graphs are shown in Figure 3.
[0057] Example 2
[0058] 1. Solution preparation
[0059] 1.1 Partial Solution Preparation
[0060] Table 1 Preparation parameters of some solutions
[0061]
[0062] 1.2 Preparation of standard stock solution and working solution
[0063] 1.2.1 Preparation of test solution
[0064] Take the Gastrodia elata decoction placed in a -20℃ refrigerator, thaw it in an ice water bath, centrifuge the sample at 4℃ 12000rpm for 15 minutes, take 300μL of sample, add 1000μL of 40℃ pre-cooled extract (methanol: water = 4:1, containing internal standard 1000:10), then vortex mix for 30 seconds, ultrasonicate in an ice water bath for 5min, let stand at -40℃ for 1h, centrifuge the sample at 4℃ 12000rpm for 15 minutes, take 200μL of supernatant and put it in an injection vial, and take another 200μL of mixed QC of equal volume and put it in an injection vial.
[0065] 1.2.2 Preparation of standard stock solution
[0066] Accurately weigh 3.79 mg of gastrodin, 3.67 mg of p-hydroxybenzyl alcohol, 4.15 mg of vanillin, 4.21 mg of barleyson glycoside A, 2.30 mg of barleyson glycoside B, 4.08 mg of barleyson glycoside C, and 3.20 mg of barleyson glycoside E, and add methanol to prepare reference solutions containing 1.26 mg / L of gastrodin, 1.22 mg / L of p-hydroxybenzyl alcohol, 1.04 mg / L of vanillin, 1.05 mg / L of barleyson glycoside A, 1.15 mg / L of barleyson glycoside B, 1.02 mg / L of barleyson glycoside C, and 1.6 mg / L of barleyson glycoside E. Pipette 1 mL of each reference solution, place it in a 10 mL volumetric flask, add methanol to make up to 10 mL, and prepare the required mixed reference solution.
[0067] 2 Pretreatment of drug-containing serum samples
[0068] Take 400 μL of sample, thaw in an ice water bath, add 40 μL of 2 mol / L hydrochloric acid, vortex for 1 min, let stand at 4°C for 15 min, repeat vortexing and let stand 4 times, add 1.6 mL of acetonitrile, vortex for 5 min, centrifuge at 12000 rpm for 5 min, take 1800 μL of supernatant, blow dry with nitrogen, add 150 μL of 80% methanol (containing internal standard 1000:10) for re-dissolution, vortex for 5 min, centrifuge at 12000 rpm for 5 min, take 120 μL of supernatant and put it in an injection vial, and take another 120 μL of mixed QC of equal volume and put it in an injection vial.
[0069] 3 Chromatographic conditions
[0070] Chromatographic column: Waters UPLC BEH C18 column (2.1mm×150mm, 1.7μm)
[0071] Mobile phase A: 0.1% formic acid in water
[0072] Mobile phase B: acetonitrile containing 0.1% formic acid
[0073] Flow rate: 0.4mL / min
[0074] Analysis time: 30min
[0075] Injection volume: 5 μL
[0076] Column temperature: 30°C
[0077] The gradient elution program is as follows:
[0078] Table 2 Liquid chromatography mobile phase conditions
[0079]
[0080] 4 Mass spectrometry conditions
[0081] AB 5600Triple T OF mass spectrometer, in each data acquisition cycle, screened out the strongest molecular ions with an intensity greater than 100 to collect the corresponding secondary mass spectrometry data. Bombardment energy: 40eV, collision energy difference: 20V, 15 secondary spectra every 50ms. The ESI ion source parameters were set as follows: atomization pressure (GS1): 55Psi, auxiliary gas pressure: 55Psi, air curtain pressure: 35Psi, temperature: 550℃, spray voltage: 5500V (positive ion mode) or -4000V (negative ion mode). Based on the mass spectrometry data of the standard and online obtained compounds, the chemical components of Gastrodia elata were obtained.
[0082] 5 Data processing
[0083] 5.1 Analysis of transitional components in rat blood
[0084] The components in the serum of rats after administration of Gastrodia elata decoction were separated and identified by retention time and mass spectrometry. The chromatograms of the drug-containing serum and blank serum samples were compared, and a total of 91 peaks were identified. There were 28 prototype components and 63 metabolites in the Gastrodia elata decoction, including 50 phase I metabolites and 13 phase II metabolites. The results showed that the main metabolic reactions of phenolic components mainly included hydroxylation, acetylation, hydrolysis, etc. The metabolic reactions of amino acids mainly included demethylation, hydroxylation, methylation, decarboxylation, oxidative deamination to alcohol, oxidative deamination to ketone, and phosphorylation. The metabolic reactions of organic acids mainly included demethylation, deethylation, methylation, hydroxylation, decarboxylation, hydrogenation, and phosphorylation. The metabolites and metabolic pathways of each component are as follows: Figure 4 The metabolic transformation pathways of gastrodin and balison glycosides in the body are shown in Figure 5 shown.
[0085] 5.2 Plotting the response intensity-time curve of each component
[0086] The drug-containing serum of rats was imported into Peakview software for identification, and 10 prototype components that responded to administration for 1 day, 3 days, 7 days, 10 days, and 14 days were screened for subsequent grey correlation calculation. These 10 prototype components are mainly phenols and organic acids, including gastrodin, p-hydroxybenzyl alcohol, p-hydroxybenzaldehyde, barisin, barisin B, barisin C, barisin E, citric acid, palmitic acid, and succinic acid.
[0087] The response intensity-time line graph of each component is shown in Figure 6 . Figure 6 The middle shows the dynamic change trend of the migrating components in rat blood. With the extension of the administration time, the response intensity of components such as gastrodin, p-hydroxybenzyl alcohol, p-hydroxybenzaldehyde, barisonoside, barisonoside B, barisonoside C, barisonoside E, palmitic acid, citric acid and succinic acid also increases. The response intensity is ranked as follows: palmitic acid> citric acid> succinic acid> barisonoside E> p-hydroxybenzaldehyde> p-hydroxybenzyl alcohol> gastrodin> barisonoside B> barisonoside C> barisonoside. As can be seen from the figure, different components have different response intensities in mass spectrometry detection and the content of each component in drug-containing serum changes at different time points.
[0088] Example 3
[0089] 1. Spectrum-effect correlation study
[0090] Compared with other analysis methods, the grey correlation analysis method has lower data requirements and can analyze small samples, so this method is more suitable for dynamic process analysis and has been widely used in the correlation analysis of Chinese medicine spectrum and efficacy. Its basic method is to determine the "contribution" of each unique peak to the efficacy based on the size of the grey correlation between the indicators of the comparison sequence and the indicators of the reference sequence. After processing the data using the mean method, the reference sequence and the comparison sequence are established, and then the correlation between the two sequences is calculated. The correlation calculation formula is:. The size of the correlation reflects the overall correlation between the reference sequence and the comparison sequence.
[0091] Spectrum-effect correlation research is an effective method to determine the active ingredients of complex mixtures and evaluate the quality of traditional Chinese medicine. Traditional Chinese medicine fingerprints have the characteristics of being holistic, macroscopic and fuzzy. Combining chemical fingerprints with biological activity evaluation to construct spectrum-effect relationships can preliminarily explore the material basis of the efficacy of traditional Chinese medicine.
[0092] 2 Correlation results analysis
[0093] Grey correlation analysis is suitable for dynamic process analysis. After the decoction of Gastrodia elata enters the body, a series of metabolic reactions occur. Based on the detection of 10 prototype chemical components that responded in the drug-containing serum of rats in each dynamic drug administration group, the response intensity changes of the above components were correlated with the dynamic changes of the efficacy indexes using the grey correlation analysis method, and the correlation coefficients of the 10 prototype chemical components in the body were obtained. The correlation coefficients of each prototype chemical component and the efficacy index are shown in Table 3.
[0094] Table 3 Grey correlation and sequencing results of 10 prototype chemical components in rat serum
[0095]
[0096] Grey correlation results showed that gastrodin, p-hydroxybenzyl alcohol, p-hydroxybenzaldehyde, barisenoside E, succinic acid, citric acid, palmitic acid, barisenoside B, barisenoside C, and barisenoside in the transitional components of rat blood were correlated with the contents of TNF-α, IL-6, IL-1β, MDA, and SOD in CIRI rats. According to the correlation ranking, gastrodin and p-hydroxybenzyl alcohol had the highest correlation, gastrodin>p-hydroxybenzyl alcohol>p-hydroxybenzaldehyde>palmitic acid>citric acid>succinic acid>barisenoside E>barisenoside C>barisenoside B>barisenoside.
[0097] Example 4
[0098] 1. Solution preparation
[0099] 1.1 Preparation of standard stock solution (Gastrodin)
[0100] Accurately weigh an appropriate amount of gastrodin reference substance and place it in a brown glass bottle that has passed the leak test. Add methanol to dissolve and shake well to prepare 1 mg / mL stock solutions, which are sealed and stored at 4°C. Take the above stock solutions and dilute them with fish farming water to different gradient concentration solutions, namely 25, 50, 100, 250, 500 and 1000 μg / mL gastrodin solutions for use.
[0101] 1.2 Preparation of standard stock solution (p-hydroxybenzyl alcohol)
[0102] Accurately weigh an appropriate amount of p-hydroxybenzyl alcohol reference substance and place it in a brown glass bottle that has passed the leak test. Add methanol to dissolve and shake well to prepare 1 mg / mL stock solutions, which are sealed and stored at 4°C. Take the above stock solutions and dilute them with fish farming water to different gradient concentration solutions, namely 25, 50, 100, 250, 500 and 1000 μg / mL p-hydroxybenzyl alcohol solutions for use.
[0103] 1.3 Preparation of standard stock solution (p-hydroxybenzaldehyde)
[0104] Accurately weigh an appropriate amount of p-hydroxybenzaldehyde reference substance and place it in a brown glass bottle that has passed the leak test. Add methanol to dissolve and shake well to prepare 1 mg / mL stock solutions, which are sealed and stored at 4°C. Take the above stock solutions and dilute them with fish farming water to different gradient concentration solutions, namely 25, 50, 100, 250, 500 and 1000 μg / mL p-hydroxybenzaldehyde solutions for use.
[0105] 2 Screening of maximum safe concentration
[0106] The present invention adopts a zebrafish embryo model, and determines the concentration-toxicity effect by detecting the survival status and teratogenic phenotype of the zebrafish after the sample acts on the zebrafish after gradient dilution concentration, and evaluates the maximum safe concentration of the zebrafish for the sample to be tested and uses it as the experimental concentration.
[0107] 3. Thrombosis detection method based on zebrafish larvae stroke model
[0108] The present invention adopts zebrafish embryos and constructs a zebrafish larvae stroke model through the modeling drug Ponatinib, and evaluates the effect of the test sample on the treatment of stroke by staining to detect thrombosis in the zebrafish brain after the test sample is treated.
[0109] 4 Data processing
[0110] 4.1 Screening results of the maximum safe concentration of gastrodin
[0111] The results of the maximum tolerance concentration of gastrodin showed that the gastrodin solutions with concentrations of 1000 μg / mL and below did not cause death or deformity in zebrafish, indicating that the maximum tolerance concentration of zebrafish to gastrodin is above 1000 μg / mL, and 1000 μg / mL can be used as a safe concentration for subsequent experiments. Figure 7 shown.
[0112] Table 4 Test results of the maximum safe concentration of gastrodia elata
[0113]
[0114] 4.2 Screening results of the maximum safe concentration of p-hydroxybenzyl alcohol
[0115] The results of the maximum tolerable concentration test of p-hydroxybenzyl alcohol showed that p-hydroxybenzyl alcohol solutions at concentrations of 100 μg / mL and below did not cause death or deformity in zebrafish, indicating that the maximum tolerable concentration of p-hydroxybenzyl alcohol for zebrafish is 100 μg / mL, and 100 μg / mL can be used as a safe concentration for subsequent experiments. p-hydroxybenzyl alcohol at concentrations of 250, 500, and 1000 μg / mL can cause zebrafish to have deformed phenotypes such as bleeding, trunk bending, skin ulceration, yolk sac necrosis, and delayed development.
[0116] 4.3 Screening results of maximum safe concentration of p-hydroxybenzaldehyde
[0117] The results of the maximum tolerable concentration test of p-hydroxybenzaldehyde showed that p-hydroxybenzaldehyde solutions at concentrations of 50 μg / mL and below did not cause death or deformity in zebrafish, indicating that the maximum tolerable concentration of p-hydroxybenzaldehyde for zebrafish is 50 μg / mL, and 50 μg / mL can be used as a safe concentration for subsequent experiments. p-hydroxybenzaldehyde at concentrations of 500 and 1000 μg / mL can cause all zebrafish to die, and p-hydroxybenzaldehyde at concentrations of 100 and 250 μg / mL can cause zebrafish to have deformed phenotypes such as bleeding, trunk bending, yolk sac necrosis, pericardial edema, and skin ulceration.
[0118] 4.4 Thrombosis test results
[0119] The results of o-dianisidine staining showed that compared with the normal treatment group, the zebrafish brain in the model control group had obvious thrombosis, indicating that the experimental model was successfully constructed. Fig.10 .
[0120] Compared with the model control group, the thrombosis and quantitative area of the positive control group (butylphthalide) were significantly reduced, and the antithrombotic effect rate was 87.8%, indicating that the results of the positive control group of this experiment were effective.
[0121] Compared with the model control group, the thrombosis formation and quantitative area of the gastrodin group were significantly decreased (p < 0.01), and the antithrombotic effect rate was 46.8%. The thrombosis formation and quantitative area of the p-hydroxybenzyl alcohol group were significantly decreased (p < 0.001), and the antithrombotic effect rate was 88.6%. The thrombosis formation and quantitative area of the p-hydroxybenzaldehyde group were significantly decreased (p < 0.001), and the antithrombotic effect rate was 84.8%. Fig.11 shown.
[0122] The overall idea of the present invention is shown in FIG. Fig.12 shown.
Claims
1. A method for screening quality markers of Gastrodia elata for improving cerebral ischemia-reperfusion injury, characterized in that: The following steps are included: S1: The Gastrodia elata medicinal material is decocted in water to obtain a decoction of Gastrodia elata, and the decoction is administered to rats with cerebral ischemia-reperfusion injury at dynamic time points, and the serum of the rats is taken to detect the efficacy indexes, and a drug efficacy-time line graph is drawn; S2: Ultra-high performance liquid chromatography-quadrupole-time of flight tandem mass spectrometry was used to qualitatively analyze the in vivo and in vitro components of Gastrodia elata decoction, analyze the migrating components in rat serum and draw a response intensity-time line graph of each component; S3: The dynamic changes of each efficacy index in S1 were correlated with the changes in the response intensity of each component in S2, and the spectrum-effect relationship of Gastrodia elata anti-inflammatory and antioxidant was constructed. The spectrum-effect correlation analysis method was used to screen out anti-inflammatory and antioxidant quality markers from the prototype chemical components in vivo.
2. The method for screening quality markers of Gastrodia elata for improving cerebral ischemia-reperfusion injury according to claim 1, characterized in that: The efficacy indicators described in step S1 include neurological deficits, cerebral infarction area, serum oxidative stress indicators and inflammatory factor indicators.
3. The method for screening quality markers of Gastrodia elata for improving cerebral ischemia-reperfusion injury according to claim 2, characterized in that: The oxidative stress indicators include MDA and SOD, and the inflammatory factors include TNF-α, IL-6, and IL-1β.
4. The method for screening quality markers of Gastrodia elata for improving cerebral ischemia-reperfusion injury according to claim 1, characterized in that: In step S2, the chromatographic conditions of ultra-high performance liquid chromatography-quadrupole-time of flight tandem mass spectrometry are: using Waters UPLC BEH C18 chromatographic column, column temperature: 30℃, flow rate: 0.4mL / min, injection volume: 5μL, mobile phase A: 0.1% formic acid water, phase B: acetonitrile containing 0.1% formic acid; gradient elution program: 0-3.5min, phase A 95-85%, phase B 5%-15%; 3.5-6min, phase A 85-70%, phase B 15%-30%; 6-6.5min, phase A 70%, phase B 30%; 6.5-12min, phase A 70-30%, phase B 30%-70%; 12-12.5min, phase A 30%, phase B 70%; 12.5-18min, phase A 30-0%, phase B 70%-100%; 18-25min, phase B 100%; 25-26min, phase A 0-95%, phase B 100%-5%; 26-30min, phase A 95%, phase B 5%; mass spectrometry conditions: using AB 5600Triple TOF mass spectrometer, bombardment energy: 40eV, collision energy difference: 20V, 15 secondary spectra every 50ms; ESI ion source parameters are set as follows: nebulizer pressure: 55Psi, auxiliary gas pressure: 55Psi, curtain gas pressure: 35Psi, temperature: 550℃, spray voltage: 5500V positive ion mode or -4000V negative ion mode.
5. The method for screening quality markers of Gastrodia elata for improving cerebral ischemia-reperfusion injury according to claim 1, characterized in that: The spectrum-effect correlation analysis method in step S3 is grey correlation analysis.
6. The method for screening quality markers of Gastrodia elata for improving cerebral ischemia-reperfusion injury according to claim 1, characterized in that: The anti-inflammatory and antioxidant quality markers described in step S3 are components with a correlation coefficient greater than 0.6 in the spectrum-effect correlation analysis.
7. The method for screening quality markers of Gastrodia elata for improving cerebral ischemia-reperfusion injury according to claim 1, characterized in that: The anti-inflammatory and antioxidant quality markers screened out in step S3 include gastrodin, p-hydroxybenzyl alcohol, p-hydroxybenzaldehyde, barisonoside, barisonoside B, barisonoside C, barisonoside E, citric acid, palmitic acid and succinic acid.
8. An application of the anti-inflammatory and antioxidant quality marker of Gastrodia elata obtained by the screening method according to any one of claims 1 to 7 in the quality detection product of Gastrodia elata, characterized in that: The anti-inflammatory and antioxidant quality markers include: gastrodin, p-hydroxybenzyl alcohol, and p-hydroxybenzaldehyde.
9. The use according to claim 8, characterized in that The anti-inflammatory and antioxidant quality markers of Gastrodia elata also include the following compounds: barisonoside, barisonoside B, barisonoside C, barisonoside E, citric acid, palmitic acid and succinic acid.
Citation Information
Patent Citations
Traditional Chinese medicine preparation for treating cerebral concussion and preparation method of traditional Chinese medicine preparation
CN104958574A
Quality control method of rhizoma gastrodiae, decoction piece thereof and rhizoma gastrodiae extract
CN107643345A
Application of gastrodin in preparation of JAK2-STAT3 signal channel inhibitor and anti-cerebral ischemia-reperfusion injury medicine
CN117547542A
Improved analysis method for pharmacodynamic material basis of Naoxinqing tablets
CN118010862A
Cinnamomi and poria composition, method to prepare same and uses thereof
US20020160059A1
